Guided Therapeutics (GTHP) Return on Sales (2010 - 2025)
Guided Therapeutics (GTHP) reported Return on Sales of 0.02% for Q4 2025, up 650.0% on a YoY basis from 0.0% in Q4 2024, and up 83.31% sequentially from 0.12% in Q3 2025.
Guided Therapeutics (GTHP) Return on Sales (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Return on Sales data on file, last reported at 0.02% in Q4 2025.
- For the quarter ending Q4 2025, Return on Sales rose 650.0% year-over-year to 0.02%; the trailing twelve-month figure through Dec 2025 stood at 0.04% (up 341.0% YoY), and the FY2025 full-year result was 0.04%, up 341.0% from the prior year.
- Return on Sales rose to 0.02% in Q4 2025, from 0.12% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.04% in Q3 2021 to a low of 24.42% in Q1 2025.
- A 5-year average of 2.5% and a median of 0.57% in 2024 frame the typical range for Return on Sales.
- Peak annual rise in Return on Sales reached 650 bps in 2025, while the deepest fall reached 2375 bps in 2025.
- Tracing GTHP's Return on Sales over 5 years: stood at 0.07% in 2021, then slumped by 4414 bps to 3.34% in 2022, then jumped by 96 bps to 0.12% in 2023, then sank by 5305 bps to 6.52% in 2024, then soared by 100 bps to 0.02% in 2025.
- Business Quant data shows GTHP's Return on Sales at 0.02% in Q4 2025, 0.12% in Q3 2025, and 0.07% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 0.00% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 0.00% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 0.00% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 0.00% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 0.00% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 0.00% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 0.00% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 0.00% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -0.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.02% |
| Sep 30, 2025 | -0.12% |
| Jun 30, 2025 | -0.07% |
| Mar 31, 2025 | -24.42% |
| Dec 31, 2024 | -6.52% |
| Sep 30, 2024 | -0.57% |
| Jun 30, 2024 | -0.57% |
| Mar 31, 2024 | -0.67% |
| Dec 31, 2023 | -0.12% |
| Sep 30, 2023 | -0.74% |
| Jun 30, 2023 | -0.35% |
| Mar 31, 2023 | -0.40% |
| Dec 31, 2022 | -3.34% |
| Sep 30, 2022 | -3.67% |
| Jun 30, 2022 | -1.85% |
| Mar 31, 2022 | -1.01% |
| Dec 31, 2021 | -0.07% |
| Sep 30, 2021 | 0.04% |
| Jun 30, 2021 | -5.17% |
| Mar 31, 2021 | -0.35% |